A Systematic Review and Meta-Analysis to Examine the Prevalence of Co-Morbid Depression in People with Type 1 and Type 2 Diabetes

2020 ◽  
Author(s):  
Aaisha Farooqi ◽  
Clare Gillies ◽  
Harini Sathanapally ◽  
Sophia C. Abner ◽  
Sam Seidu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Meta Analysis

Prevalence and risk factors of fatigue in type 1 and type 2 diabetes: A systematic review and meta‐analysis

2021 ◽  
Author(s):  
Debby Syahru Romadlon ◽  
Faizul Hasan ◽  
Bayu Satria Wiratama ◽  
Hsiao‐Yean Chiu
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Type 2 Diabetes ◽  
Meta Analysis

scholarly journals The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: A systematic review and meta-analysis update

Bone ◽  
2020 ◽  
Vol 137 ◽  
pp. 115457 ◽  
Author(s):  
Tatiane Vilaca ◽  
Marian Schini ◽  
Susan Harnan ◽  
Anthea Sutton ◽  
Edith Poku ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Vertebral Fractures ◽  
Meta Analysis

scholarly journals Incidence and prevalence of hypoglycaemia in type 1 and type 2 diabetes individuals: A systematic review and meta-analysis

2020 ◽  
Vol 170 ◽  
pp. 108522
Author(s):  
Hassan Alwafi ◽  
Alaa A. Alsharif ◽  
Li Wei ◽  
Dean Langan ◽  
Abdallah Y. Naser ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Meta Analysis

scholarly journals Clinical efficacy and safety of insulin aspart compared with regular human insulin in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis

2015 ◽  
Vol 125 (3) ◽  
pp. 141-151
Author(s):  
Piotr Wojciechowski ◽  
Patrycja Niemczyk-Szechowska ◽  
Elżbieta Olewińska ◽  
Patrycja Jaros ◽  
Barbara Mierzejewska ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Human Insulin ◽  
Clinical Efficacy ◽  
Insulin Aspart ◽  
Meta Analysis ◽  
Regular Human Insulin ◽  
Efficacy And Safety

scholarly journals The Efficacy of Mobile Phone Apps for Lifestyle Modification in Diabetes: Systematic Review and Meta-Analysis (Preprint)

2018 ◽  
Author(s):  
Xinghan Wu ◽  
Xitong Guo ◽  
Zhiwei Zhang
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Mobile Phone ◽  
Lifestyle Modification ◽  
Meta Analysis ◽  
Short Term

BACKGROUND Diabetes and related complications are estimated to cost US $727 billion worldwide annually. Type 1 diabetes, type 2 diabetes, and gestational diabetes are three subtypes of diabetes that share the same behavioral risk factors. Efforts in lifestyle modification, such as daily physical activity and healthy diets, can reduce the risk of prediabetes, improve the health levels of people with diabetes, and prevent complications. Lifestyle modification is commonly performed in a face-to-face interaction, which can prove costly. Mobile phone apps provide a more accessible platform for lifestyle modification in diabetes. OBJECTIVE This review aimed to summarize and synthesize the clinical evidence of the efficacy of mobile phone apps for lifestyle modification in different subtypes of diabetes. METHODS In June 2018, we conducted a literature search in 5 databases (Cochrane Central Register of Controlled Trials, MEDLINE, Embase, CINAHL, and PsycINFO). We evaluated the studies that passed screening using The Cochrane Collaboration’s risk of bias tool. We conducted a meta-analysis for each subtype on the mean difference (between intervention and control groups) at the posttreatment glycated hemoglobin (HbA1c) level. Where possible, we analyzed subgroups for short-term (3-6 months) and long-term (9-12 months) studies. Heterogeneity was assessed using the I2 statistic. RESULTS We identified total of 2669 articles through database searching. After the screening, we included 26 articles (23 studies) in the systematic review, of which 18 studies (5 type 1 diabetes, 11 type 2 diabetes, and 2 prediabetes studies) were eligible for meta-analysis. For type 1 diabetes, the overall effect on HbA1c was statistically insignificant (P=.46) with acceptable heterogeneity (I2=39%) in the short-term subgroup (4 studies) and significant heterogeneity between the short-term and long-term subgroups (I2=64%). Regarding type 2 diabetes, the overall effect on HbA1c was statistically significant (P<.01) in both subgroups, and when the 2 subgroups were combined, there was virtually no heterogeneity within and between the subgroups (I2 range 0%-2%). The effect remained statistically significant (P<.01) after adjusting for publication bias using the trim and fill method. For the prediabetes condition, the overall effect on HbA1c was statistically insignificant (P=.67) with a large heterogeneity (I2=65%) between the 2 studies. CONCLUSIONS There is strong evidence for the efficacy of mobile phone apps for lifestyle modification in type 2 diabetes. The evidence is inconclusive for the other diabetes subtypes.

scholarly journals MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover – a systematic review and meta-analysis

2017 ◽  
Vol 176 (3) ◽  
pp. R137-R157 ◽  
Author(s):  
Katrine Hygum ◽  
Jakob Starup-Linde ◽  
Torben Harsløf ◽  
Peter Vestergaard ◽  
Bente L Langdahl
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Type 2 Diabetes ◽  
Bone Resorption ◽  
Bone Turnover ◽  
Meta Analysis ◽  
Patients With Diabetes ◽  
Low Bone Turnover

Objective To investigate the differences in bone turnover between diabetic patients and controls. Design A systematic review and meta-analysis. Methods A literature search was conducted using the databases Medline at PubMed and EMBASE. The free text search terms ‘diabetes mellitus’ and ‘bone turnover’, ‘sclerostin’, ‘RANKL’, ‘osteoprotegerin’, ‘tartrate-resistant acid’ and ‘TRAP’ were used. Studies were eligible if they investigated bone turnover markers in patients with diabetes compared with controls. Data were extracted by two reviewers. Results A total of 2881 papers were identified of which 66 studies were included. Serum levels of the bone resorption marker C-terminal cross-linked telopeptide (−0.10 ng/mL (−0.12, −0.08)) and the bone formation markers osteocalcin (−2.51 ng/mL (−3.01, −2.01)) and procollagen type 1 amino terminal propeptide (−10.80 ng/mL (−12.83, −8.77)) were all lower in patients with diabetes compared with controls. Furthermore, s-tartrate-resistant acid phosphatase was decreased in patients with type 2 diabetes (−0.31 U/L (−0.56, −0.05)) compared with controls. S-sclerostin was significantly higher in patients with type 2 diabetes (14.92 pmol/L (3.12, 26.72)) and patients with type 1 diabetes (3.24 pmol/L (1.52, 4.96)) compared with controls. Also, s-osteoprotegerin was increased among patients with diabetes compared with controls (2.67 pmol/L (0.21, 5.14)). Conclusions Markers of both bone formation and bone resorption are decreased in patients with diabetes. This suggests that diabetes mellitus is a state of low bone turnover, which in turn may lead to more fragile bone. Altered levels of sclerostin and osteoprotegerin may be responsible for this.

Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis

2018 ◽  
Vol 56 (3) ◽  
pp. 355-364 ◽  
Author(s):  
Ana Díez-Fernández ◽  
Iván Cavero-Redondo ◽  
Jesús Moreno-Fernández ◽  
Diana P. Pozuelo-Carrascosa ◽  
Miriam Garrido-Miguel ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Insulin Glargine ◽  
Meta Analysis ◽  
Nocturnal Hypoglycemia

Diagnostic Accuracy of Neutrophil Gelatinase-Associated Lipocalin for Predicting Early Diabetic Nephropathy in Patients with Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

2019 ◽  
Vol 4 (1) ◽  
pp. 78-94 ◽  
Author(s):  
Georgia V Kapoula ◽  
Panagiota I Kontou ◽  
Pantelis G Bagos
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Type 2 Diabetes ◽  
Meta Analysis ◽  
Healthy Individuals ◽  
Neutrophil Gelatinase Associated Lipocalin ◽  
Neutrophil Gelatinase ◽  
Serum And Urine

Abstract Background Currently, there is a lack of prediction markers for diabetic nephropathy (DN) in patients with type 1 and type 2 diabetes mellitus (T1DM/T2DM). The aim of this systematic review and meta-analysis was to evaluate the value of a promising biomarker, neutrophil gelatinase-associated lipocalin (NGAL), in both serum and urine for the diagnosis of early DN in T1DM and T2DM patients with different stages of albuminuria. Methods A comprehensive search was performed on PubMed by 2 reviewers until September 2018. Studies in which (a) the degree of DN was determined according to the urinary albumin/creatinine ratio and (b) NGAL was measured in healthy individuals and in diabetes patients with DN were included in the meta-analysis. For each study, a 2 × 2 contingency table was formulated. Sensitivity, specificity, and other estimates of accuracy were calculated using a bivariate random effects model. The hierarchical summary ROC method was used to pool data and to evaluate the area under the curve (AUC). The sources of heterogeneity were explored by subgroup analysis. Publication bias was assessed using the Deeks test. Results The meta-analysis enrolled 22 studies involving 683 healthy individuals and 3249 patients with diabetes, of which 488 were T1DM and 2761 were T2DM patients. Overall, pooled sensitivity and specificity among the different settings analyzed ranged from 0.42 (95% CI, 0.22–0.66) to 1.00 (95% CI, 0.99–1.00) and 0.72 (95% CI, 0.62–0.80) to 0.98 (95% CI, 0.50–1.00) in T2DM patients, respectively. For T1DM patients, the corresponding estimates were 0.71 (95% CI, 0.59–0.81) to 0.89 (95% CI, 0.64–0.97) and 0.72 (95% CI, 0.62–0.80) to 0.79 (95% CI, 0.67–0.87). The AUC of NGAL for T2DM patients ranged from 0.69 (95% CI, 0.65–0.73) to 1.00 (95% CI, 0.99–1.00) in the different settings. Conclusion The results of this meta-analysis suggest that NGAL in both serum and urine can be considered a valuable biomarker for early detection of DN in diabetes patients.

Sign in / Sign up

Export Citation Format

Share Document